The human salivary antimicrobial peptide profile according to the oral microbiota in health, periodontitis and smoking by Grant, Melissa et al.
 
 
The human salivary antimicrobial peptide profile
according to the oral microbiota in health,
periodontitis and smoking
Grant, Melissa; Kilsgård, Ola ; Åkerman, Sigvard ; Klinge, Björn ; Demmer, Ryan  ;




Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Grant, M, Kilsgård, O, Åkerman, S, Klinge, B, Demmer, R, Malmström, J & Jönsson, D 2018, 'The human
salivary antimicrobial peptide profile according to the oral microbiota in health, periodontitis and smoking',
Journal of Innate Immunity. https://doi.org/10.1159/000494146
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
checked for eligibility 8/1/19
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Research Article
J Innate Immun
The Human Salivary Antimicrobial Peptide Profile 
according to the Oral Microbiota in Health, 
Periodontitis and Smoking
Melissa Grant a    Ola Kilsgård b    Sigvard Åkerman c, d    Björn Klinge e, f    
Ryan T. Demmer g, h    Johan Malmström b    Daniel Jönsson c, f    
a
 School of Dentistry, Institute of Clinical Sciences, University of Birmingham and Birmingham Community 
Healthcare Foundation Trust, Birmingham, UK; b Division of Infection Medicine, Department of Clinical Sciences 
Lund, Lund University, Lund, Sweden; c Swedish Dental Service of Skåne, Lund, Sweden; d Department of Orofacial 
Pain and Jaw Function, Faculty of Odontology, Malmö University, Malmö, Sweden; e Division of Periodontology, 
Department of Dental Medicine, Karolinska Institutet, Solna, Sweden; f Department of Periodontology, Faculty of 
Odontology, Malmö University, Malmö, Sweden; g Division of Epidemiology and Community Health, University 
of Minnesota, Minneapolis, MN, USA; h Department of Epidemiology, Mailman School of Public Health, Columbia 
University, New York, NY, USA
Received: March 16, 2018
Accepted after revision: October 1, 2018




Department of Periodontology, Faculty of Odontology
Malmö University
SE–205 06 Malmö (Sweden)
E-Mail daniel.jonsson @ mau.se
© 2018 The Author(s)





Antimicrobial peptides · Periodontitis · Inflammation · 
Saliva
Abstract
Antimicrobial peptides (AMPs) are a diverse family of pep-
tides that defend the mucosal surfaces of the oral cavity and 
other locations. Many AMPs have multiple functions and 
properties that influence aspects of innate defense and colo-
nization by microorganisms. The human oral cavity is home 
to the second-most diverse microbiome, and the health of 
the mouth is influenced by the presence of these bacteria as 
well as by extrinsic factors such as periodontitis and smok-
ing. This study hypothesized that the AMP profile is different 
in the presence of extrinsic factors and that this would also 
be reflected in the bacteria present. The AMP profile was an-
alyzed by quantitative selected-reaction-monitoring mass 
spectrometry analysis and 40 bacterial species were quanti-
fied by DNA-DNA hybridization in saliva donated by 41 indi-
viduals. Periodontal status was assessed through dental ex-
amination and smoking status through medical charting. 
Periodontal health (in nonsmokers) was associated with 
a higher abundance of ribonuclease 7, protachykinin 1, 
β-defensin 128, lipocalin 1, bactericidal permeability-in-
creasing protein fold-containing family B member 3, and 
bone-marrow proteoglycan. Nonsmoking periodontal dis-
ease was associated with an abundance of neutrophil defen-
sin 1 and cathelicidin. However, 7 AMPs were overabundant 
in periodontal disease in smokers: adrenomedullin, eosino-
phil peroxidase, 3 different histones, myeloperoxidase, and 
neutrophil defensin 1. There were no differentially abundant 
AMPs in smokers versus nonsmokers with periodontal 
health. Correlation network inference of healthy nonsmok-
ers, healthy smokers, nonsmoking periodontitis, or smoking 
periodontitis donors demonstrated very different networks 
growing in complexity with increasing numbers of stressors. 
The study highlights the importance of the interaction be-
tween the oral cavity and its resident microbiota and how 
this may be influenced by periodontal disease and smoking.
© 2018 The Author(s)
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Salivary antimicrobial peptides (AMPs) are the first 
line of innate defense in the oral and gastrointestinal sys-
tem. The antimicrobial capacity of saliva permits coloni-
zation of the oral cavity but prevents extensive microbial 
colonization of the oral and oropharyngeal tissues. A sud-
den absence of salivary flow, e.g., in intensive care pa-
tients [1], causes increased inflammation in the oral gin-
giva and mucosa, probably due to the increased oropha-
ryngeal colonization of potential pathogenic microor-
ganisms [1]. Long-term attenuation of salivary flow, as in 
xersostomia, is also associated with an increased inci-
dence of caries lesion as well as oral fungal infections [2]. 
The reason why xerostomia causes oral diseases and per-
mits microbiological overgrowth in the oropharyngeal 
tissues is due to the physical capacity of saliva to wash 
away, and thereby inhibit the growth of, microbiological 
biofilms, but also because of the rich variety of salivary 
AMPs.
The salivary AMPs range from the relatively large ag-
glutinating mucins to the smaller membrane-perforating 
cathelicidins and defensins [3]. With respect to the large 
variety of smaller peptides, their individual antimicrobial 
capacity and their relevance in oral disease have been the 
focus of many studies. For example, a lack of cathelicidin 
LL-37 has been suggested to be the biological mechanism 
responsible for the aggressive periodontitis in subjects 
with Kostmann syndrome [4]. Interestingly, many AMPs 
also possess proapoptotic and proinflammatory proper-
ties. Our group, as well as others, have reported that cat-
helicidin LL-37 has antimicrobial and LPS-neutralizing 
properties at low concentrations but proapoptotic at 
higher levels [5, 6]. Similarly, the chemoattractant CCL28 
displays chemotactic activity as well as broad-spectrum 
antimicrobial activity [7].
In other tissues, such as in the lung and the intestinal 
crypts, AMPs reach levels of bactericidal activity, keeping 
microbial activity at very low levels [8]. The oral cavity is 
constantly being exposed to bacterial, viral, and fungal 
activity, and is dependent on a symbiosis between a 
strong resident microbiome and the innate immune re-
sponses for the maintenance of health. In the oral cavity, 
the AMPs do not reach the same levels as in the lung, al-
lowing microorganisms to inhabit the oral cavity. The 
oral AMPs do, however, reach the levels at which they 
can neutralize bacterial products such as LPS [5, 9], 
thereby disarming the bacteria and changing the ability 
of some microorganisms to compete to inhabit the oral 
cavity. However, the influence of AMPs on the composi-
tion of oral microbial communities is, by and large, un-
known.
Certain conditions create an oral milieu that is more 
favorable for oral dysbiosis, such as environmental fac-
tors like smoking and systemic factors like diabetes. 
Smoking has been widely investigated in its role in peri-
odontitis risk and increases this risk approximately 6-fold 
[10]. To our knowledge, no studies have investigated the 
impact of smoking and periodontal disease on the sali-
vary AMP profile.
The oral microbiota is the second-most complex mi-
crobial community in the human body and, like the gut, 
interacts with the immune system to induce tolerance of 
commensal organisms. Pathogenic organisms can pro-
liferate in diseases of the oral cavity such as periodonti-
tis, and they cause inflammatory and immune responses 
that are equivalent to the microorganisms themselves (if 
not more important) in the destruction of soft tissues. 
Initial characterization of the oral flora is part of the his-
tory of microscopy [11], but techniques used in the past 
2 decades, such as DNA-DNA hybridization, estab-
lished the importance of the complexes defined by So-
cransky et al. [12] for periodontal disease. More recent-
ly, next-generation sequencing has elaborated on the 
complexities of the oral microbiome. Socransky et al. 
[12] used mathematical modeling to define complexes, 
denoted by colors, that were associated with clinical-
measures periodontal disease (red complex), whereas as 
others were associated with bacteria found to bridge 
health and disease (orange complex), or in periodon-
tally healthy donors (yellow complex). These classifica-
tions have been used greatly in research into periodontal 
disease.
The hypothesis of this study was that saliva constitutes 
an AMP profile with specific AMPs or clusters of AMPs 
that may be correlated with certain bacteria or clusters of 
bacteria. We also hypothesize that the AMP profile may 
be different under certain circumstances, e.g., in smokers 
and subjects with periodontal disease. Knowledge of 
which AMPs cluster with which microbes in healthy and 
dysbiotic conditions will allow for future studies to inves-
tigate if the AMP profile can be an instrument by which 
healthy oral microbiota can be sculptured. The aim of this 
study was to map the human salivary AMP profile and 
investigate which AMPs correlate with certain bacterial 
clusters. A second aim was to investigate which AMPs are 
up- or downregulated in subjects with periodontitis, both 
smokers and nonsmokers.






One thousand subjects, representative of the population of 
Skåne County in Sweden, were selected from the Swedish Govern-
ment’s Person Address Register, SPAR. Individuals between the 
ages of 20 and 89 years were selected. Of these 1,000 subjects, 451 
underwent a dental clinical examination, had their medical history 
recorded, and had saliva collected. Of these 451 subjects, 41 diabe-
tes-free individuals were selected based on their periodontal status 
and smoking habits. Periodontal disease was defined as having 
bone loss (BL) of ≥1/3 of the root length and/or a pocket depth of 
> 5 mm as well as bleeding on probing (BoP) > 20%. Among sub-
jects with the most severe periodontitis, 10 nonsmokers (defined 
as never or former smokers) and 9 current smokers with the high-
est number of pockets with a probing depth of 4–5 mm were se-
lected. Periodontal health was defined as not having any teeth with 
a periodontal probing depth > 5 mm and no bone loss > 1/3 of the 
root length. Among the periodontally healthy, 11 nonsmokers and 
11 current smokers were frequency-matched by age based on the 
corresponding periodontitis/smoking status group.
Clinical Examination
The dental clinical examination has been reported previously 
[13]. It included radiographs, i.e., bitewing radiographs in the pre-
molar and molar areas as well as a panoramic radiograph. Peri-
odontal pockets exceeding 3 mm were recorded at 4 sites of each 
tooth using an Hu-Friedy 1-mm-graded periodontal probe. The 
presence or absence of plaque and bleeding on probing were also 
recorded. Bone loss on panoramic radiographs corresponding to 
> 1/3 of the root length was noted as well.
Medical History
Medical history charting included questions on blood pressure, 
cardiovascular disease (CVD), diabetes, rheumatic diseases, and 
other diseases. Any medication prescribed by a doctor was also 
recorded. The medical history also included questions on present 
or past usage of tobacco, Swedish snuff, and smoking. Smoking 
status was recorded from the medical charting and participants 
were defined as never/former smokers or current smokers.
Sampling and Saliva Handling
Saliva was harvested by having the subject chew on a sterile 
piece of paraffin for 5 min and expectorate into a tube. The sample 
was immediately frozen at –20  ° C and later at –80  ° C. At a later 
time point, the saliva was thawed and spun down to allow the for-
mation of a pellet and a supernatant. The pellet was analyzed by 
checkerboard DNA-DNA hybridization with respect to 40 differ-
ent oral species, and the supernatant was used for proteomics.
Checkerboard DNA-DNA Hybridization
The salivary pellet was sent to the Forsyth Institute in Boston on 
dry ice for further handling. At the Forsyth, the pellet was resus-
pended in sterile Tris-EDTA buffer and each sample was individu-
ally analyzed using checkerboard DNA-DNA hybridization with 
respect to 40 different species representing commensal oral micro-
flora as well as bacteria associated with caries and periodontitis: A. 
naeslundii, S. constellatus, E. nodatum, P. gingivalis, A. actinomy-
cetemcomitans, F. nucleatum subsp. vincentii, C. rectus, T. socran-
skii, E. saburreum, P. micra, V. parvula, A. oris, S. anginosus, S. 
sanguinis, H. pylori, S. oralis, C. ochracea, A. israelli, S. intermedia, 
T. denticola, S. mutans, P. nigrescens, A. odontolyticus, F. nucleatum 
subsp. polymorphum, C. showae, F. periodonticum, N. mucosa, F. 
nucleatum subsp. nucleatum, C. gingivalis, S. gordonii, T. forsythia, 
S. noxia, S. salivarius, P. melaninogenica, S. mitis, E. corrodens, G. 
morbillorum, C. sputigena, L. bucallis, C. gracilis, and P. intermedia.
Preparation of Saliva
The total protein concentration of saliva supernatant was as-
sessed using the Bradford assay: 10 µg of salivary protein was di-
luted with HPLC-grade water up to 20 µL and denatured with 10 M 
urea and 100 mM ammonium bicarbonate (Sigma-Aldrich). Subse-
quently, the samples were submitted to in-solution digestion. First, 
the protein samples were reduced with 5 mM Tris-2-carboxyethyl 
phosphine (TCEP, Sigma-Aldrich) at 37  ° C for 60 min. 10 mM of 
2-Iodoacetamide (IAA) was then added to the samples and they 
were incubated in the dark for 30 min. Samples were diluted 5× in 
0.1 M ammonium bicarbonate before trypsin digestion (2.5 ng/µL) 
was performed overnight at 37  ° C. The next morning, 10% formic 
acid (FA) was added to terminate the reaction until the pH reached 
2–3. For all dilutions, HPLC-grade water was used (Sigma-Al-
drich). The C18 peptide clean-up protocol was performed after-
wards using Harvard Apparatus C18 Macro SpinColumns 
(#744101), according to the manufacturer’s protocol. Samples were 
reconstituted in 2% acetonitrile (ACN) and 0.1 % FA in water.
Selected-Reaction-Monitoring Mass Spectrometry
To construct a selected-reaction-monitoring mass spectrome-
try (SRM-MS) method capable of quantifying AMPs in saliva, we 
selected 117 proteins from previous MS experiments, microarray 
data [14, 15], and the literature [3], and synthesized 340 peptides 
corresponding to AMPs within the 117 proteins. The 20 most in-
tense fragments of each peptide were estimated from previously 
acquired shotgun MS data, and the resulting 6,800 transitions were 
subsequently tested on the triple quadrupole mass spectrometer. 
These efforts generated SRM-MS assays for all the 117 proteins 
covered by at least 1 peptide per protein and at least 6 transitions 
per peptide. At the same time, we recorded the retention time off 
the chromatography column to enabled scheduled SRM-MS anal-
ysis, and then established the reference library needed to automat-
ically score the results generated from the saliva samples with our 
software analysis tools [16]. The produced data were processed 
through an in-house-developed software pipeline [17]. The SRM-
MS measurements were performed on a TSQ Vantage triple quad-
rupole mass spectrometer (QqQ) or a TSQ Quantiva QqQ (both 
from Thermo Scientific). Chromatographic separations of pep-
tides were performed with Easy-nLC II systems (Thermo Scien-
tific). Peptides were loaded with a constant pressure rate of 280 
bars onto the analytical columns, either PicoChip (PCH7515-
105H354-FS25, New Objective) or EasySpray (ES802, Thermo Sci-
entific) with 10 µL of 97% solvent A (0.1% FA in water) and 3% 
solvent B (0.1% FA in ACN). The peptides were eluted with a linear 
gradient from 92% solvent A and 8% solvent B to 35% solvent B 
over 10 or 34 min with a constant flow of 300 nL/min. The raw data 
were acquired using Xcalibur software (Thermo Scientific) and 
then processed and analyzed with SRM-MS analysis software Sky-
line38 with manual validation and inspection of the results. This 
included retention times, similarity between library spectra and 
acquire data (dotp), and the similarity of relative fragment ion in-





Statistics and Data Analysis
Data were analyzed using SPSS v23. The correlation between 
peptide and bacterial quantities was calculated using the Spearman 
correlation. Fold-change of AMPs and bacteria were calculated 
based on the raw data values. Due to data normality distribution, 
the raw data were log10-transformed to allow for parametric tests. 
ANCOVA analysis was used to compare between group fold-
change in AMP quantity. The ANCOVA analysis was adjusted for 
age. p < 0.05 were considered statistically significant.
Heat maps were made with R-based ClustVis [18] using log10-
transformed peptide quantities or untransformed bacterial quanti-
ties. Rows and columns were clustered using Manhattan distance 
and average linkage. Peptides present in < 75% of all samples were 
excluded from the heat maps. Network graphs were generated using 
Gephi [19] using statistically significant correlations with r > 0.75. 
Specifically, the nodes represent the AMPs and bacteria investigated 
here. These nodes are connected by lines (edges) showing the posi-
tive (red) and negative (green) correlations between the analytes. 
Correlations within the AMPs or bacterial groups alone have not 
been investigated and are not shown here. The size of each node 
shows the proportional size compared to the overall average detect-
ed. The width of the edges shows the strength of the correlation with 
greater width equating to stronger correlation. Where correlations 
between analytes are less than r = 0.75 and p = 0.05, edges are not 
shown. Unconnected nodes were removed for clarity of viewing.
Results
Table 1 describes the demographic characteristics, to-
bacco usage, and periodontal parameters of all parti-
cipants. From the cohort of 41 subjects, there were 10 
nonsmoking and 9 smoking subjects with periodontal 
disease. The periodontally healthy smokers were signifi-
cantly younger than smokers with periodontal disease. 
Participants with periodontitis (vs. periodontally healthy) 
had lower tooth counts, and an increased bleeding index, 
prevalence, and proportion of deep periodontal pockets 
(all p < 0.05).
AMP Profile
A total of 63 antimicrobial proteins and peptides were 
detected in saliva (online suppl. Table 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000494146) by 
SRM-MS and are visualized in Figure 1 with the associated 
demographic data. Online supplementary Figure 1 includes 
graphical representation of the abundance of all peptides 
based on the 4 groups (periodontitis, healthy, periodontitis 
in smokers, and healthy smokers). The highest quantity of 
peptide was found for neutrophil-derived neutrophil de-
fensin 1.
In total, 5 peptides were significantly more abundant 
in periodontal healthy donors versus diseased subjects af-
ter age adjustment, namely ribonuclease 7 (RNase 7), 
protachykinin 1, β-defensin 128, bactericidal permeabil-
ity-increasing fold-containing family B member 3 (BPIB3) 
and bone-marrow proteoglycan. Lipocalin 1 was only sig-
nificantly abundant in healthy in a t test comparison, but 
not after adjustment for age in an ANCOVA analysis of 
covariance (Table 2). As demonstrated in Table 2, neutro-
Table 1. Demographic and dental status of the whole cohort, subdivided into subjects with periodontal disease, periodontally healthy, 
smokers, non-smokers, diabetics and non-diabetics
All Perio nonsmoker Healthy nonsmoker Perio smoker Healthy smoker
Subjects, n 41 10 11 9 11
Age, years 50.1±16.3 51.3±17.8§ 44.8±12.3 51.3±15.0§ 33.2±11.2
Female gender 20 (48.8) 5 (50) 6 (54.5) 4 (44) 5 (45.5)
Current smoker 20 (48.8) 0 (0) 0 (0) 9 (100) 11 (100)
Never-smoker 13 (31.7) 4 (40) 9 (81.8) 0 (0) 0 (0)
Former smoker 8 (19.5) 6 (60) 2 (18.2) 0 (0) 0 (0)
Swedish snuff user 4 (9.8) 1 (10) 1 (9.1) 0 (0) 2 (18.2)
Tooth count 25.0±4.0 24.5±4.1§ 27.1±1.0 22.3±3.8§ 26.8±1.5
BoP, % 37.1±27.4 69.1±23.9§ 5.9±9.4 47.8±18.2§ 26.2±21.6
Prevalence, PPD ≥6 mm 2.8±4.8 9.7±6.3§ 0 5.8±4.0§ 0
No/mild periodontitis 22 (53.7) 0 (0) 11 (100) 0 (0) 11 (100)
Moderate/severe periodontitis 19 (46.3) 10 (100) 0 (0) 9 (100) 0 (0)
Values express n (%) or mean ± SD, unless otherwise indicated. BoP, bleeding on probing; PPD, probing pocket depth; Perio, with 
periodontal disease.
§ Significantly different compared to the corresponding nonexposed group (perio nonsmoker vs. healthy nonsmoker and perio 
smoker versus healthy smoker). 




Fig. 1. Visualization of all peptide signatures for all samples. Peptide data were log10-transformed, as shown on 
the scale bar for colors. Imputation is used for missing value estimation. Missing data squares are represented in 






phil defensin 1 and cathelicidin were overabundant in 
periodontal disease in nonsmokers. The relative over-
abundance of AMPs in smokers with periodontal disease 
compared to healthy smokers was 2- to 2.6-fold; neutro-
phil defensin 1 and cathelicidin were overabundant in 
nonsmokers with periodontitis and healthy nonsmokers 
by 3.3-fold and 2.2-fold, respectively. An age-adjusted 
ANCOVA analysis resulted in no statistically significant-
ly abundant AMPs in smokers with periodontal disease 
and healthy smokers, but in nonsmokers the AMPs stayed 
significant.
The relative abundance of AMPs in subjects with peri-
odontal disease and periodontally healthy subjects was 
statistically significant for 7 peptides in a t test compari-
son, but in none when adjusting for age in the ANCOVA 
analysis. In smokers, adrenomedullin, eosinophil peroxi-
dase (EPX), histone (H)2A type 2A, H2B type 2E, H2B 
type F-S, myeloperoxidase (MPO) and neutrophil defen-
sin 1 were all overabundant in periodontal disease com-
pared to healthy subjects. There was no difference in the 
abundance of specific AMPs in periodontally healthy 
smokers versus nonsmokers (Table 3).
Bacterial Profile
Checkerboard DNA-DNA hybridization was used to 
target 40 different oral bacterial species representing 
commensal oral microflora as well as bacteria associated 
with caries and periodontitis. All the bacteria were de-
tected in at least 52% of the saliva samples, with a me-
dian detection rate of 95%. The data are visualized in 
Figure 2.
Correlation between AMPs and Bacteria
A correlation matrix comparing AMP and bacterial 
relationships in the whole cohort (Fig. 3) was construct-
ed to illustrate the pattern of AMP-bacteria correlation 
across all samples. It is apparent that there are 3 groups 
of peptides in these correlations: those predominantly 
positively correlated (in purple); those predominantly 
negatively correlated (in green); and some that showed 
a mixed response across the bacteria and peptides. The 
more positively correlated peptides and bacteria appear 
to have peptides that could be derived from an immune 
response, i.e., MPO, EPX, histones, and S100 proteins. 
Therefore, an exploration of only the most highly cor-
related (r > 0.75) and significantly (p < 0.05) correlated 
peptides and bacteria were examined for groups of pa-
tients. Figure 4 shows the network graphs generated by 
this analysis. It is clear to see that there are few signifi-
cant and highly correlated nodes in healthy nonsmok-
ing participants; however, the number of nodes and 
connections (edges) increases with both smoking and 
periodontal disease. In healthy smokers, higher quanti-
ties of salivary peptides such as cystatins as well as CGRP 
and yellow complex bacteria (e.g., S. mutans and S. sal-
ivarius) appear (Fig.  4). In periodontitis patients, a 
greater quantity of the red complex bacterium P. gingi-
valis becomes apparent alongside more neutrophil-de-
rived peptides such as neutrophil defensin 1. In peri-
odontal smokers, there is a much more complex and 
connected network with high quantities of S100 pro-
teins potentially derived from lysing neutrophils. Ac-
cordingly, the average degree increases across the net-
Table 2. Differential abundance of AMPs among nonsmoking participants who were periodontally healthy and 





p on log value
ANCOVA (age-adjusted)
Ribonuclease 7 nPnS/PnS 19.3 0.001 0.001
Protachykinin 1 nPnS/PnS 3.7 0.01 0.006
β-Defensin 128 nPnS/PnS 3.5 0.002 0.0005
Lipocalin 1 nPnS/PnS 2.9 0.049 0.065
BPIB3 nPnS/PnS 2.3 0.025 0.009
Bone-marrow proteoglycan nPnS/PnS 2.1 0.015 0.02
Neutrophil defensin 1 nPnS/PnS 0.3 0.034 0.048
Cathelicidin nPnS/PnS 0.45 0.006 0.007
p values are based on Student’s t test and ANCOVA adjusted for age for independent samples on log10-
transformed levels of AMPs. BPIB3, bactericidal permeability-increasing fold-containing family B member 3; 
nPnS, nonsmokers with no periodontal disease; PnS, nonsmokers with periodontal disease.












































Fig. 2. Visualization of all bacterial signatures for all samples. Bacterial data were log10-transformed, as shown on 
the scale bar for colors. Imputation is used for missing value estimation. Missing data squares are represented in 






























































































































































































































































Fig. 3. Clustering of AMP abundance based 
on correlation to bacterial abundance. Pur-
ple represents positive correlation and 
green represents negative correlation.




works (healthy nonsmokers 1.2, healthy smokers 2.3, 
periodontitis nonsmokers 3.4, and periodontitis smok-
ers 7.4), with concomitant increases in the number of 
nodes and edges.
Discussion
This study has mapped the relative abundance of 63 
AMPs and the presence of 40 bacterial species known to 
be important in the oral cavity. It has investigated corre-
lations between specific AMPs and clusters of AMPs with 
bacterial species, and clusters of species, and determined 
Healthy smokersHealthy nonsmokers
Perio smokersPerio nonsmokers
Fig. 4. Network analysis of significantly correlated (Spearman correlation: r > 0.75, p < 0.05) peptides and bacte-
ria. Network graphs drawn with Gephi using Fruchterman-Reingold layout and no overlap. Size of node is pro-
portional to the average quantity detected in the condition relative to overall average. Node colors denote bacte-






which salivary AMPs are more/less abundant in peri-
odontal health and disease in the presence or absence of 
the most important risk factor of periodontal disease, 
namely smoking.
Of the 63 AMPs, there was a wide variation between 
individual donors; however, higher quantities of various 
AMPs could be associated with either health or disease, or 
with or without smoking. When examined for different 
roles, it could be seen that clusters of diverse salivary 
AMPs were found together rather than clustering of AMPs 
with similar functions. This type of clustering has been 
observed previously by Choi et al. [20], who demonstrated 
that P. gingivalis LPS-binding proteins in whole saliva 
could be detected alongside high frequencies of diverse 
AMPs, including cystatins, lipocalin 1, and perforin 1.
Some AMPs were of particular interest as they have 
either rarely been investigated or appear to be new to in-
vestigations into periodontitis. In our data, RNase 7 was 
19 times overabundant in periodontal health versus dis-
ease in nonsmokers and correlated inversely with most 
bacteria. RNase 7 is strongly cationic and specifically ex-
pressed in the epithelial cells of the skin, and the respira-
tory and genitourinary tracts, and is induced by inflam-
matory agents and bacterial infection [21]. Interestingly, 
RNAse 7 is found more abundantly in skin samples from 
travelers unaffected by Staphylococcus aureus-positive 
skin infection than in travelers with S. aureus-positive 
skin infection, suggesting that it plays a role in the main-
tenance of healthy, noncolonised health states [22]. RNase 
7 has, to our knowledge, not been studied in the context 
of periodontal disease previously.
Protachykinin is also more abundant in periodontal 
health and has not previously been reported in its own 
right. However, it is a precursor of substance P and sub-
stance K. Substance P is a well-known neurotransmitter 
and neuromodulator with antimicrobial capacity [23]. 
Substance P is reportedly upregulated in inflammation, 
but a recent paper from Haririan et al. [24] confirmed 
higher salivary levels of substance P in healthy subjects 
than in subjects with periodontal disease.
When examining how AMP abundance correlated with 
bacterial species in all the samples, a cluster of highly cor-
related AMPs and bacteria could be seen (Fig. 3). These 
AMPs included cystatins A and D, BPIFB4, CCL28, MPO, 
and EPX, lactotransferrin, platelet basic protein, and PG-
LYRP1. Many of these peptides are of leukocyte, particu-
larly neutrophil, origin. The bacterial species vary, being 
Gram-positive or Gram-negative, and they belong to the 
range of complexes in Socransky et al. [12]. Notable ab-
sences though, are the bacteria most associated with peri-
odontal disease, the red complex bacteria. Periodontal le-
sions have an abundance of neutrophils and, even in health, 
these leukocytes are travelling through the periodontium 
to appraise the microbe-rich environment of the oral cav-
ity. It is possible that the abundance of these peptides and 
these bacteria represent an induction of a robust immune 
response by species that are easily recognized by the body.
Notable inverse correlations were observed between 
cystatins SN, S, and SA, and many bacterial species 
(Fig. 3). These proteins are part of the cystatin superfam-
ily: 2 of the families are represented in family 1, the stefins 
(cystatins A–D), and in family 2 cystatins (SA, S, and SN). 
Family 1 members lack disulfide bonds whereas family 2 
members have 2 internal disulfide bonds; it seems that 
family 2 has a much lower inhibitory activity [25]. Per-
haps the role of family 2 cystatins differs from the more 
Table 3. Differential abundance of AMPs in periodontally healthy smokers versus smokers with periodontal 
disease
Peptide Group Fold change p value1 p value2
Adrenomedullin PS/nPS 2.3 0.04 0.602
Eosinophil peroxidase PS/nPS 2.2 0.025 0.153
Histone H2A type 2A PS/nPS 2.6 0.028 0.183
Histone H2B type 2E PS/nPS 2.2 0.046 0.310
Histone H2B type F-S PS/nPS 2.0 0.042 0.245
Myeloperoxidase PS/nPS 2.3 0.014 0.101
Neutrophil defensin 1 PS/nPS 2.3 0.021 0.082
p values are based on Student’s t test and ANCOVA adjusted for age for independent samples on log10-
transformed levels of AMPs: 1 unadjusted; 2 adjusted for age. nPS, smokers with no periodontal disease; PS, 
smokers with periodontal disease.




efficient role played by family 1 in cysteine protease inhi-
bition. Cystatins S, SA, and SN are generally expressed 
extracellularly, in saliva, tear fluid, and blood [26]. Previ-
ous studies have shown that cystatin SA can inhibit the 
growth of both P. gingivalis and A. actinomycetemcomi-
tans, potentially through a surface-binding mechanism 
rather than by inhibiting protease activity [27, 28].
When examining the data as a whole by correlation 
network analysis (Fig. 4), healthy nonsmoking individu-
als showed a very sparsely connected network, suggesting 
a capacity to adapt to changes, but perturbation of the 
healthy condition by either smoking or periodontitis al-
ters this to create correlated networks that have many 
more connections and potential interdependencies. In 
the periodontitis nonsmoking samples, cystatin D was 
positively correlated with 16 bacteria. This saliva peptide 
inhibits the cathepsin cysteine proteinases and has the 
highest preference for cathepsin S [29]. Cathepsin S is 
produced by many cell types, including leukocytes, sug-
gesting that the correlation with bacteria may indicate an 
increased leukocyte response which the salivary glands 
are trying to contain. In the periodontitis smoker samples 
there was a negative correlation between the S100 pep-
tides (A7–A9) and many bacteria, forming a dense cluster 
of interactions. S100A8 and A9 form the heterodimer, 
calprotectin, which has broad-spectrum antimicrobial 
activity [30] reflected by the numerous bacteria in these 
donors. In the periodontitis smoker samples, there were 
also negative correlations with prolactin-inducible pro-
tein (PIP) and lysozyme C. PIP is produced by the salivary 
glands and has multiple functions including the proteoly-
sis of fibronectin [31] and the agglutination of bacteria, 
including Streptococci [32]. Lysozyme C is a glycosyl 
hydrolase with well-known bacteriolytic functions pro-
duced widely, including by the salivary glands. The nega-
tive correlation of these peptides with various species of 
bacteria may indicate differential routes for the manipu-
lation of the oral microbiome.
When designing this study, we used a broad approach 
for the definition of AMPs; however, there may be pep-
tides with antimicrobial features reported in the saliva 
that we were not able to detect with the design that we 
deployed, and we may also have included peptides with 
questionable antibacterial activity. Online supplementary 
Table 1 presents a detailed description of all AMPs by full 
name and UniProt code. Some of the AMPs quantified 
here are precursors of the form that exerts antibacterial 
activity, but they are still considered relevant in this set-
ting (e.g., cathelicidin is quantified here but not its active 
form LL-37). In the case of BPI, we were able to detect 
both BPI and its precursor BPI CAP57, which are pre-
sented separately.
In order to capture both bacteria and AMPs, we chose 
the model of using salivary supernatant for peptides and 
pellet for bacteria. The model may be criticized, as cat-
ionic peptides can bind to larger molecules that may end 
up in the pellet. Also, free 16S rRNA is lost using this de-
sign. On the other hand, cationic peptides, such as cathe-
licidin and defensins are highly abundant in this study, 
and as the study focused on AMPs, it was beneficial to 
exclude abundant free 16S rRNA from devitalized bacte-
ria. One benefit of using salivary supernatant and pellet is 
that less saliva is needed, allowing the inclusion of sub-
jects with a low salivary flow. An alternative approach 
would have been to use the site-specific gingival crevicu-
lar fluid (GCF) which flows into the saliva. GCF is regu-
larly used in biomarker analysis in periodontal disease 
and it is rich in AMPs. However, in this study, the interest 
lay in the analysis of the fluid in the whole mouth. Focus-
ing on GCF may have provided even greater insight into 
AMP regulation of the oral microbiota, but no GCF sam-
ples were available.
The ideal design of this study would be to include all 
451 subjects of the cohort, but this was not feasible due to 
the expense and the length of time associated with SRM-
MS analysis. When selecting subjects from a larger cohort, 
there is the question of prioritizing the exposure variable 
or the proper matching of confounding variables. Here, 
we prioritized the exposure variable “periodontitis”, as the 
variable “smoking” is included based on its impact on 
periodontitis. The periodontal health diagnosis here fo-
cused on pocket depth and bone loss, which unfortunate-
ly allowed for the inclusion of subjects with gingivitis.
Another selection of participants, to more accurately 
elucidate the impact of smoking, would be to sort smokers 
based on pack years. That would, however, compromise 
the main objective of the study, i.e., to elucidate the asso-
ciation of periodontitis and AMPs. Adjustment for age 
was in the form of 2 steps: (i) including younger periodon-
titis subjects and older healthy subjects, and (ii) analyzing 
covariance using ANCOVA, allowing for adjustment.
The cells, tissues, and fluids of the oral cavity allow 
bacterial colonization, but it is the innate immune re-
sponse and especially the salivary AMPs that dictate the 
milieu that will promote the colonization of certain bacte-
rial species. This study was an attempt to capture that in-
teraction. Our data also show the shift in AMP profile 
from health to periodontal disease, and in smokers versus 
nonsmokers with and without periodontal disease, sug-





pacts the pathogenesis of periodontal disease. The data 
from this study will result in future oral AMP-related re-
search focusing on the reported AMPs.
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